ABSTRACT. We have previously demonstrated that N-benzylaminoferrocene-based prodrugs are activated in the presence of the cancer-specific levels of reactive oxygen species (ROS) and are toxic towards several cancer cell lines and primary cells, but non-toxic to representative normal cells (Marzenell, P. et al, J. Med. Chem., 2013, 56(17), 6935; Hagen, H. et al, J. Med. Chem., 2012, 526(2), 924). Herein we report on a substantially improved method of synthesis of these compounds with a yield of up to 90 %. We demonstrate its applicability by preparing nine new aminoferrocenes and scaling up successfully the synthesis of the most active prodrug 4 (4-(N-ferrocenyl-N-benzylaminocarbonyloxymethyl)-phenylboronic acid pinacol ester) up to 2 g, which was required for further in vivo experiments reported in this paper. Next, we studied the effects of aminoferrocenes on the viability of selected cancer cell lines (JVM-2, RAJI, BL-2 and HL-60) and primary chronic lymphoid leukemia (CLL) cells having different p53 status (wild type, mutated or completely absent). The obtained data were in agreement with the hypothesis that the toxicity of aminoferrocenes is not dependent upon p53 status. Subsequently the toxicity of prodrug 4 was investigated ex vivo using rat precision cut liver slices (PCLS). Interestingly, prodrug 4 was found to exhibit substantial toxicity (IC 50 = 3.8 + 1.3 µM) in freshly prepared PCLS, which initially contained a low amount of glutathione (GSH). In contrast, it was found to be non-toxic up to the highest tested concentration (10 µM) in PCLS pre-incubated for 24 h, that 3 contained a normal GSH amount. Since this low amount of GSH is likely to correlate with a high intracellular oxidation state, these data are in agreement with the reported mode of activation of aminoferrocenes. In addition, we demonstrated that intraperitoneal administration of a single dose of up to 6 mg/kg of prodrug 4 does not affect the weight and the survival of hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) for at least 21 days after injection. Finally, in a preliminary in vivo experiment prodrug 4 was shown to extend the survival of hybrid male mice BDF1 carrying L1210 leukemia from 13.7 + 0.6 days to 17.5 + 0.7 days when injected daily for 6 times at a dose of 26 µg/kg (cumulative dose: 0.156 mg/kg) starting from the second day after injection of L1210 cells. We confirmed that the antitumor activity of prodrug 4 correlates with the increase of the oxidative stress in L1210 cells isolated from treated animals, which is reflected in the higher intracellular ROS concentration and damage of the cellular membrane. All together our data indicate that aminoferrocene-based prodrugs can potentially be applied for the treatment of cancers, which express mutated or no p53 and are often poorly responsive to the conventional chemotherapy.
INTRODUCTION
The intracellular milieu of cancer cells differs substantially from that of normal ones. This difference can be utilized to design cancer specific, ROS-sensitive prodrugs. 1 In particular, the concentration of reactive oxygen species (ROS= 1 O 2 , O 2
In particular, bleomycin coordinates intracellular iron ions (present in excess in cancer cells) resulting in the formation of a potent catalyst for cleavage of genomic DNA. 4 Hydroxyferrocifens and organochalcogenes are oxidized to glutathione (GSH) scavengers and ROS-generating catalysts, respectively; thus, inducing cell death via oxidative stress. 5, 6 Furthermore, pro-alkylating agents, such as SN-38 and aminoferrocenes are activated by the cleavage of a C-B bond in the presence of cancer-specific H 2 O 2 concentrations. 8, 9 In the case of aminoferrocenes two toxic products are obtained, one of them being a ROS-generating catalyst and the other a GSH scavenger. These products act synergistically on each other leading to a strong elevation of ROS concentration in cancer cells causing their death. The dual mode of action of aminoferrocenes is unique. 9 The only other drug reported up to date, acting by a related mechanism, is [( 6 -arene)Ru(azpy)I] + . 10 In particular, this compound first oxidizes GSH to GSSG. Then, the reduced complex is oxidized by O 2 to give the initial complex and H 2 O 2 .
However, in contrast to aminoferrocenes this compound is not a prodrug. Therefore, it can potentially affect also normal cells. Moreover, the oxidized product (GSSG) can be recovered by intracellular reductases thereby diminishing the effect of the drug. In contrast, products released from aminoferrocenes irreversibly modify glutathione by alkylating it.
9
In previous work we have demonstrated that selected aminoferrocenes are active against primary chronic lymphoid leukemia (CLL) cells, 9b However, in this preliminary study the genetic status of CLL cells was not determined. Nevertheless, it is well documented that CLL is a genetically heterogeneous disease and some CLL-types exhibit poor prognosis. 11 For example, TP53-mutated CLL is poorly responsive to standard therapy. The TP53 gene encodes tumor suppressor p53, a protein participating in cell cycle regulation. Therefore, search for new drugs for the treatment of TP53-mutated CLL and other hematological cancers is warranted. Since the mode of action of aminoferrocenes relies on ROS-induced chemical activation that is not directly related to TP53, 9 it is probable that these prodrugs will be active against both wild type and TP53 mutated/negative hematological cancers. Herein, we discuss a new series of data proving this hypothesis using three B-cell derived cancer cell lines with different TP53-status and primary CLL cells with defined TP53 status. Moreover, we report on studies of toxicity and antitumor activity of a selected aminoferrocene (compound 4, Scheme 1) using rat precision cut liver slices (ex vivo), and BDF1 (DBA/2,♀ x C57Bl/6,♂) mice carrying TP53-mutated L1210 leukemia (in vivo). For these biological experiments a large amount of prodrug 4 (up to 2 g) was required, which was obtained using a substantially improved method of synthesis of N-benzylated aminoferrocenes. We also demonstrated the general applicability of this method by preparing nine new N-substituted aminoferrocenes.
RESULTS AND DISCUSSION

Synthesis of N-alkylated aminoferrocene-based prodrugs
The previously reported procedure for preparation of compound 4 yielded under optimized conditions only ~5 % of the product. 9 It consisted of reductive amination of commercially available aminoferrocene 1 in the presence of benzaldehyde and Na[B(CN)H 3 ] with formation of N-benzylaminoferrocene 2, followed by coupling of compound 2 to 4-(hydroxymethyl)phenylboronic acid pinacol ester in toluene in the presence of triphosgene at 120
°C for 24 h (steps a, b in Scheme 1). Since the intermediate product 2 is unstable in air, these two Scheme 1. Outline of tested pathways for optimization of synthesis of N-alkylated aminoferrocene-based prodrugs a: RR'C=O, NaB(CN)H 3 ; b: 4-hydroxymethylphenylboronic acid pinacol ester, Cl 3 COC(O)OCCl 3 , 120 °C; 9 c: same as b; d: benzyl chloride, Cs 2 CO 3 , tert-butylamonium iodide (TBAI); e: 1,2-di-(chloromethyl)benzol, Cs 2 CO 3 , TBAI; f: compound 3, Cs 2 CO 3 , TBAI.
steps were conducted in a one pot reaction. We observed that changes of conditions including (1) optimization of the reductive amination combined with isolation of compound 2, (2) replacement of triphosgene either for N,N'-carbonyldiimidazole (CDI) or CDI/CH 3 I mixture or 4-nitrophenyloxycarbonylchloride and (3) increasing nucleophilicity of the hydroxyl group of 4-hydroxymethylphenylboronic acid pinacol ester by its deprotonation on the presence of NaH led to further reduction of the yield of the desired product. Moreover, application of substituted benzaldehydes in this reaction sequence with an attempt to prepare analogues of compound 4 was hampered by even lower yields. The latter effect was especially pronounced for pyridinecarboxaldehydes and 2-and 4-substituted benzaldehydes carrying either electron donating substituents like OMe, NMe 2 or CH 3 or thermally and hydrolytically unstable substituents like OAc or NHAc. Therefore, an alternative approach for synthesis of compound 4 was developed. In particular, we used compound 3 as a starting material. In contrast to 2, compound 3 is highly stable and can be obtained from commercially available starting materials in large quantities with 74 % yield. 9a We attempted alkylation of compound 3 (1) under optimized Mitsunobu conditions for carbamates, 12 using benzyl alkohol, Bu 3 P and 1,1'-(azidodicarbonyl)dipiperidine (ADDP); (2) in the presence of Cs 2 CO 3 using BnCl/(NBu 4 )I mixture as an electrophile under conditions of Salvatore et al 13 ; and (3) in the presence of NaH using either benzyl chloride or bromide as electrophiles as described elsewhere for other starting materials.
14 Though the first approach delivered only traces of the product, the other two reaction conditions led to clean conversion of compound 3 into 4. Isolated yields of analytically pure compound 4 varied in the range between 71 and 92 %, which is substantially improved with respect to the previously reported synthetic protocol (5 %). We confirmed that this method is suitable for scaling up the synthesis of compound 4 up to 2 g. We also used this protocol to prepare nine new analogues of 4, including compounds, containing differently substituted phenylmethyl and pyridylmethyl moieties. In particular, in the series of compounds 4, 5, 6
electron deficiency of the Ph-rest is modulated by substituents in the 3 rd position: H, F, OMe. In compound 7 the para-hydroxy group is protected as an acetic acid ester. In cells it is expected to be deprotected via hydrolysis forming the highly electron rich 4-hydroxyphenylmethylcontaining aminoferrocene, which will be partially deprotonated at pH 7 with formation of the phenolate ion (pK a ~ 9-10). In contrast, 2-and 3-pyridyl-residues in compounds 8 and 9 are strongly electron deficient. At pH 7 they are expected to remain neutral (pK a~ [5] [6] . Compound 10 is derived from 4 by substitution of a benzyl for a diphenylmethyl residue. It is obtained by alkylation of intermediate 3 with diphenylmethylchloride with the relatively low yield of 6 %.
The latter result reflects the low reactivity of the corresponding electrophile due to its steric bulkiness. Compound 10 is the first example of the aminoferrocene-based prodrug where the carbon atom connected to the nitrogen atom of the aminoferrocene core carries two substituents (phenyl residues in this case). Synthesis of such derivatives using the initially applied protocol was not possible since the reductive amination product formed from aminoferrocene 1 and ketones in step a is not reactive in the following step b (Scheme 1). Since all steps in the new protocol were conducted at 22 °C, thermally unstable or reactive substrates could be applied. For example, compound 11, which carries 2-chlormethyl residue could be prepared from equimolar mixture of compound 3 and 1,2-di(chlormethyl)benzene. The product was isolated with the yield of 34%. X-ray single crystal diffraction analysis allowed to determine the structure of compound 11 ( Figure 1 ), which is the first crystallographically characterized aminoferrocene-based prodrug. These data confirm the atom connectivity suggested based on the synthesis, 1 H NMR spectroscopy and mass spectrometry of 11. The geometry of a ferrocene unit in compound 11 is similar to that in other known alkyloxycarbonylaminoferrocenes.
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(C2, N1, C3, O1, O2) are located in a plane, which is inclined by 24° to the plane of the cyclopentadienyl ligand containing atoms C42, C41 and C45 ( Figure 1 ). These data are indicative of only weak conjugation between the ferrocene unit and the carbamate fragment. The fully planar conformation is not realized due to the expected clash between the bulky substituents at N1 atom with the hydrogen atoms attached to C42 and C45 atoms. It is evident that a fragment -H 2 C1-Cl1 is not hindered by other atoms in structure 11 (Figure 1 ). Therefore, we expected that it is accessible to nucleophilic reagents. In agreement with this expectation, we observed that 11 reacts with excess 3 with formation of doubly substituted product 12. We are currently exploring 11 for conjugation of the aminoferrocene core to other nucleophilic modifiers, e.g. those, which can either target these prodrugs to specific compartments in cells (e.g. nuclei or mitochondria) or direct them to cancer cells. Analogously to mono-aminoferrocene-based compound 3, 1,1'-bisaminoferrocene-based compound 13 can be efficiently alkylated at the optimized conditions producing doubly N-benzylated product 14 with the yield of 55 % (Scheme 2). In this case the yield is slightly lower than that observed in the alkylation of compound 3 -71-92 %.
Thus, the synthetic method described above expands our possibilities in the modification of the N-substituent in aminoferrocenes at the sites indicated with red arrows in Scheme 1, whereas the previously used protocol allowed only modifications at the sites indicated with blow arrows and was restricted to thermally stable substrates. Moreover, it allows scaling-up the synthesis of Nsubstituted aminoferrocenes that enables their thorough structural, spectroscopic and biological studies.
Scheme 2. Synthesis of doubly-modified aminoferrocenes using the developed improved synthetic protocol and structures of controls.
a: BnCl, Cs 2 CO 3 , TBAI.
Effects of prepared prodrugs on the viability of B-cell-derived cancer cell lines having different TP53-status
To explore the role of p53 in the mode of action of aminoferrocene-based prodrugs we studied their effects on the viability of three selected B-cell derived cancer cell lines with different TP53 status. The human mantle cell lymphoma (MCL) was represented by the JVM-2 cell line. MCL accounts for ~7 % of all lymphoid malignancies and has relatively poor prognosis due to almost invariable relapse occurring after initial chemotherapy. 16 The JVM-2 cell line contains wild type (wt) p53 and an additional t(11;14) translocation. The human Burkitt lymphoma was represented in our panel by RAJI and BL-2 cell lines. Notably, mutated p53 is expressed in RAJI, whereas wt p53 in BL-2 cells. Moreover, in RAJI a translocation t (8, 14) as well as Epstein-Barr-Virus (EBV+) are detected, whereas in BL-2 a translocation t (8, 22) is present. The latter cell line is EBV negative. 17 The promyelocytic human leukemia cell line HL-60, which expresses no detectable p53 protein and p53 mRNA and whose TP53 gene underwent major deletions, 18 was also included for comparison (Table 1) .
First, we determined the relative amounts of intracellular reactive oxygen species in JVM-2, RAJI and BL-2 by using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA)-based assay as described earlier. 9 In particular, we observed that the relative mean fluorescence ( i no p53 -wt p53 is not expressed; mut p53 -mutated p53; wt p53 -active (wild type) p53 is expressed. Data are given as mean of at least three independent experiments + SD. ND -not determined.
ii Structure of prodrugs and their labeling scheme are given in Schemes 1 and 2.
can be determined to be equal to 1.8 + 0.5, that in JVM-2 cell line to be 1.5 + 0.1 and that in BL-2 cell line 1.4 + 0.1. These data indicate that, within the experimental error, compound 4
permeates equally well through the membranes of all studied cell lines.
Furthermore, we studied the viability of three selected B-cell derived cancer cell lines and of HL-60 cell line in the presence of known (3, 4, 13) and newly prepared aminoferrocene-based prodrugs by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Table 1) . Among the new aminoferrocenes reported in this paper, only compound 11, which contains a 2-CH 2 Cl residue in the N-benzyl substituent, turned out to be substantially more toxic towards all cell lines tested than the parent compound 4 (p< 0.01). We can speculate that in this case the stronger cytotoxic effect could be caused by alkylation of endogenous nucleophilic moieties, e.g. thiol groups of GSH or proteins, by the 2-CH 2 Cl residue. At this point other possible mechanisms, e.g. enhanced uptake of this compound, cannot be excluded. Since the experiments with the CLL cells (as described below) were performed with medium containing human serum (HS), whereas the cell lines were incubated in medium with fetal calf serum (FCS), we investigated whether the replacement of FCS by HS in experiments with HL-60 cells affects the toxicity of compound 11 as well as that of reference compound 4. We observed that while the effect of compound 4 was not dependent on the type of the serum used, the toxicity of 11 was fully inhibited in the HS-containing medium even at the highest concentration of the drug used (50 µM). Furthermore, in experiments with CLL cells compound 11 exhibited no toxicity at concentrations of up to 10 µM (data not shown). These data indicate that HS is able to scavenge in some way compound 11. Since the only structural difference between compounds Independent of the mechanism of the latter process, it may preclude the possible anticancer activity of compound 11 in vivo. Therefore, this prodrug was not selected for further biological tests.
It is worth noting that neither the substitution of 3-and 4-H-atoms in the phenyl residue for either electron donating or accepting moieties (compounds 5, 6, 7) nor the replacement of the phenyl rest with 2-and 3-pyridyl moieties (compounds 8, 9) affected the activity of aminoferrocenes substantially. Furthermore, substitution of the N-benzyl residue for Ndiphenylmethyl (compound 10) only slightly enhanced the activity towards the cancer cell lines RAJI (IC 50 = 21 + 4 µM for 10 versus 35 + 6 µM for 4, p<0.05) and BL-2 (IC 50 = 16 + 1 µM for 10 versus 25 + 1 µM for 4, p<0.01), whereas its effect on two other cell lines (HL-60 and JVM-2) was found to be negligible (Table 1) . Unfortunately, the N-benzylation of the carbamate group of a 1,1'-bis-aminoferrocene-derived prodrug did not exhibit the analogous favorable effect as the same derivatization of the mono-aminoferrocenes (compare 13, 14 and 3, 4, Table 1 ).
We observed that the resistance of wt p53-expressing BL-2 and JVM-2 cell lines as well as mut p53-expressing RAJI cell line towards aminoferrocenes is similar for the majority of the prodrugs studied here, except that in a few cases (compounds 7, 8 and 9) the BL-2 cell line was found to be slightly more sensitive than RAJI and JVM-2 cell lines (Table 1) . Overall, these data support the hypothesis that the anticancer activity of aminoferrocene-based prodrugs does not require p53 activity.
Effect of aminoferrocenes on the viability of wild type and TP53-mutated/deleted chronic lymphocytic leukemia cells
Subsequently, we investigated the effects of two representative aminoferrocene-based prodrugs mutated CLL cells and 17 patients had wild type p53 CLL cells. The effect of compounds 3 and 4, as well as of fludarabine on the viability of CLL cells was determined by using ATPlite™ Luminescence Assay System (PerkinElmer, Waltham, USA). Fludarabine is a purine analogue, which is currently used as a standard treatment of the CLL disease. The mode of action of this drug depends upon p53, 19 making it more active against wt p53 cancer types. Therefore, treatment of CLL patients with fludarabine can cause a selective survival of p53-mutant CLL cells, which are more resistant and, therefore, less responsive to the therapy. We observed that after treatment of p53-mutated CLL cells (8 patients Their toxicity turned out to be practically independent of the status of p53 in CLL cells ( Figure   2 ). These data are in agreement with our results obtained for B-cell-derived cell lines (see above)
and support the hypothesis that the mode of action of aminoferrocenes is not dependent upon p53. This advantageous property can make these prodrugs potentially suitable for the treatment of p53-mutated CLL and other hematological cancers.
Ex vivo and in vivo toxicity of aminoferrocene 4
Based on the preliminary studies obtained so far, we selected compound 4 for further evaluation of its toxicity ex vivo and in vivo. We have previously shown that this prodrug is not toxic towards normal (non-cancer) cells including fibroblasts (< 100 µM) and primary mononuclear cells (MNC's, < 10 µM).
9 In order to validate these in vitro data in a more complex experimental model, we first investigated the toxicity of compound 4 ex vivo using rat precisioncut liver slices (PCLS) according to established procedures. 20 PCLS are viable explants of tissue with a reproducible and well-defined thickness, containing cells in their natural environment.
Notably, this technique is an FDA-approved model for drug toxicity and metabolism studies, and it has been applied already for the assessment of toxicity of cisplatin 21 and experimental goldbased compounds. 22 In this assay liver cells remain in their natural environment and therefore, the obtained toxicity results are expected to be more relevant than those obtained earlier in experiments with cell cultures.
Thus, rat liver slices were cut and pre-incubated either for 1 h or 24 h before exposure to the prodrug as detailed in the experimental section, to allow the cells to recover from the cold ischemia and the slicing procedure. After pre-incubation, slices were incubated in fresh WEGG medium containing 2.5 µM, 5 µM or 10 µM of compound 4 for a period of 24 h. Afterwards they were collected and the viability of the tissues was determined measuring the ATP content.
The choice of the pre-incubation time appeared to be crucial: A marked decrease in the viability of 1 h pre-incubated slices was already found at a concentration of 5 µM prodrug (Figure 3 ). In contrast, slices pre-incubated for 24 h remained practically fully viable (83 %) even at the highest tested concentration (10 µM, Figure 3 ). Since aminoferrocenes are activated and as such expected to be more toxic under oxidative conditions 9 , we may speculate that after 1 hour preincubation the slices are subject to oxidative stress due to the organ excision and slicing procedure increasing their sensitivity to compound 4. Indeed, others have reported that shortly after slice preparation the GSH concentration in the slices is low. 23 In contrast, after 24 h preincubation slices reach a more physiological equilibrium, which is reflected in normal intracellular GSH concentration. 23 Preliminary experiments exploring the toxicity of cisplatin in liver slices have shown that no effect of pre-incubation exists for this compound (data not shown). This indicates that the effect of pre-incubation is probably related to the specific toxic mechanism of aminoferrocenes. Taken together these data confirm that in normal (nonmalignant) cells, which are characterized by low ROS concentration, aminoferrocenes remain inactive. 9 Furthermore, experiments were carried out with ferrocene 15 as a negative control and 17 as a positive control (Scheme 2). Both compounds were added to slices pre-incubated for 24 h, and incubation was continued for additional 24 h. As expected, ferrocene 15 showed no reduction in viability even at 40 µM, whereas compound 17 showed a high toxicity with an IC 50 of ca. 1 µM.
Based on the promising in vitro 9 and ex vivo data on the toxicity of prodrug 4, we decided to further study its effects on healthy hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) at variable treatment. These data suggest that prodrug 4 exhibits no fulminant toxicity in vivo at concentrations of up to 6 mg/kg, although more subtle effects cannot be excluded.
Antitumor activity of prodrug 4 in vivo
Finally, antitumor activity of 4 was evaluated on hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂), which carry L1210 leukemia, expressing mutant p53. 17 In an exploratory experiment the treatment of mice (15 animals per group) was started on the second day after injection of L1210 cells. It included six daily intraperitoneal injections of compound 4 at a dose of 26 µg/kg in PBS solution (0.5 mL) containing 0.2 % (v/v) DMSO (total dose: 0.156 mg/kg).
The control groups received the same volume of PBS solution. We observed that survival of the mice was extended from 13.7 + 0.6 days in the control group to 17.5 + 0.7 days in the treated group (p<0.05). This corresponds to 28 % lifetime extension that according to Sofina et al 24 indicates a significant antitumor effect thereby justifying further investigations of prodrug 4. It has been previously reported that 7 days after intraperitoneal injection of L1210 in BDF1 mice (DBA/2,♀ x C57Bl/6, ♂) ascites fluid of the animals contains over 93 % of L1210 cells with respect to the total cell number. 25 In order to evaluate the drug-induced oxidative stress, we took probes of ascites fluid of treated and control groups and analyzed mitochondria integrity (JC-1 assay) and the intracellular ROS amount (CM-H2DCF DA assay) in the L1210 cells that were present in this sample. In particular, the fluorescence of L1210 cells isolated from the drugtreated animals and incubated with the JC-1 probe was found to be 97. 
CONCLUSIONS
We developed a substantially improved method for synthesis of N-substituted aminoferrocenebased prodrugs, which leads to yields of 72-91 %. In contrast, by using the previous method these compounds could be obtained with yields of under 5 %. 9 In the key step, easily accessible starting material 4-(ferrocenylaminocarbonyloxymethyl)-phenylboronic acid pinacol ester was alkylated by variable benzyl chlorides or bromides at 22 °C, whereas in the previously used protocol prolonged heating at 120 °C was required. 9 Therefore, heat sensitive building blocks could be introduced by the new approach, including for example an N-(4-acetyloxyphenyl)methyl substituent. Overall, nine new N-substituted prodrugs were prepared by this protocol, which were obtained in high purity and amount and required limited purification.
Thus, we were able to characterize the biological effects of the new series of compounds in vitro, ex vivo and in vivo. First, we observed that the prodrugs exhibit similar toxicity towards B-cell derived hematological cancer cell lines (JVM-2, RAJI and BL-2) having different p53 status.
Subsequently, we confirmed that the toxicity of aminoferrocenes is practically independent from the p53 status in primary CLL cells. In preparation to the in vivo studies of the antitumor activity of the prodrugs, we confirmed that compound 4 exhibits practically no toxicity up to 10 µM in precision cut liver slices pre-incubated for 24 h up (ex vivo), and up to 6 mg/kg in hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂) (in vivo). Finally, the antitumor activity of the most active prodrug 4 was studied in hybrid male mice BDF1 (DBA/2,♀ x C57Bl/6, ♂), which carry L1210 leukemia. We observed that compound 4 administered in 6 daily doses of 26 µg/kg extends the survival of the mice from 13.7 + 0.6 days to 17.5 + 0.7 days. The prolonged survival was accompanied by increased oxidative stress of and membrane damage in L1210 cells isolated from the ascites fluid of treated animals. It is worth mentioning that the dose used in the in vivo antitumor experiment is much lower than the maximum texted dose of the in vivo toxicity studies, where no weight loss of the animals has been observed. Although further studies are necessary to validate the mechanisms of action of this new class of compounds, as well as more advanced toxicity studies, our findings indicate that these aminoferrocene prodrugs can potentially be applied for the treatment of cancers, which express mutated or no p53 and are often poorly responsive to the conventional chemotherapy.
EXPERIMENTAL SECTION
General Information
Commercially available chemicals of the best quality from Aldrich/Sigma/Fluka (Germany) were obtained and used without purification. Starting materials 1-3 (Scheme 1), 13 (Scheme 2) and control compounds 16 and 17 (Scheme 2) were prepared as described previously. 9 NMR spectra were acquired on a Bruker Avance 400 or Bruker Avance III 600 spectrometer. ESI mass spectra were recorded on a Bruker ESI MicroTOF II. C, H, and N analysis was performed in the microanalytical laboratory of the chemical institute of the Fiedrich-Alexander-University of Erlangen-Nürnberg. UV-vis spectra were measured on a Lambda Bio+ UV/Vis spectrophotometer (Perkin Elmer) by using quartz glass cuvettes (Hellma GmbH, Germany) with a sample volume of 1 mL or micro-cuvettes with a sample volume of 100 µL (BRAND GmbH, Germany). The fluorescence of live cells was quantified using a Guava easyCyte TM 6-2L Flow cytometer from Merck Millipore. The data were processed using the inCyte TM software package from Merck Millipore and the ModFIT LT TM software from Verity Software House. The purity of the prodrugs used in the biological tests was determined by C, H, and N analysis. According to these data, the purity of the prodrugs and controls was greater than 95%. Crystal structure data for prodrug 11 ( Figure 1 ) were submitted to the Cambridge Structural Database (CSD). This structure was assigned the deposition number CCDC 1011896. (27.8 mg, 19 .3 µL 163 µmol) was added and the reaction was stirred for 2 h at 22 °C. Then, the solvent was removed in vacuum (0.01 mbar) and the product was purified by column chromatography on silica gel using petroleum ether/acetone (4/1, v/v) as eluent. Yield: 55 mg, 100 µmol (92%).
Synthesis
Compound 5 was prepared analogously to compound 4 using protocol 1. 164.65, 162.23, 142.57, 140.30, 135.11, 130.78, 127.47, 122.65, 114.02, 113.81, 113.65, 113.43, 84.08, 69.28, 67.49, 64.68, 62.81, 62. 135.14, 129.92, 127.50, 118.84, 112.55, 112.46, 101.79, 84.09, 69.28, 68.86, 67.37, 64.59, 62.82, 54.98, 53.71, 24.76 168.30, 156.22, 14λ.51, 13λ.47, 135.85, 134.27, 126.99, 126.76, 121.47, 121.19, 83.20, 69.31, 68.71, 68.44, 68.35, 68.06, 63.73, 23. 149.26, 140.72, 135.61, 135.23, 134.85, 128 .00 (two overlapping peaks), 124.20, 102.15, 84.57, 69.77, 68.03, 65.23, 63.25, 52.07, 25.20 Then, the solvent was removed in vacuum (0.01 mbar) and the product was purified by column chromatography on silica gel using DCM -DCM/ethylacetate (4/1, v/v) followed by a second column using petroleum ether/acetone (6/1, v/v) . The product was isolated as orange solid.
Yield: 78 mg, 124 µmol (6%). TLC (SiO 2 , eluent petroleum ether/acetone, 4/1, v/v) R f = 0. Compound 11. Compound 3 (500 mg, 1.08 mmol) was dissolved in anhydrous DMF (25 mL) under a nitrogen atmosphere. Then Cs 2 CO 3 (4.24 g, 13.01 mmol) and TBAI (4.79, 13.01 mmol) were added to the solution. After stirring for 30 minutes at 22 °C, 1,2-bis(chloromethyl)benzene (569 mg, 3.25 mmol) was added. The mixture was stirred for 18 hours at 22 °C. Then, the solvent was removed in vacuum (0.01 mbar) and the product was purified by column chromatography on silica gel using petroleum ether/acetone (6/1, v/v) 24, 138.70, 136.50, 134.80, 134.46, 134.18, 133.25, 129.99, 128.96, 126.68, 125.01, 83.41, 69.76, 68.76, 67.21, 63.94, 62.14, 50.51, 43.82, 24. δ (ppm) 154.68, 140.35, 135.41, 135.16, 127.2λ, 127.18, 125.66, 102.05, 84.10, 6λ.33, 67.42, 64.68, 62.91, 51.38, 24.76 35, 13λ.16, 135.16, 128.82, 128.46, 127.53, 127.24, 126.87, 126.70, 102.22, 84.08, 67.40, 65.72, 63.49, 53.04, 24.75 H 6.38, N 3.06; found -C 68.09, H 6.45, N 3.11 .
Cellular Assays
Cells and Cell Culture. FBS, 1% L-glutamine, and 1% penicillin/streptomycin. All cells studied here are non-adherent.
Stock suspensions of the cells were grown up to 0.5-1.5 x 10 6 cells/mL and diluted as required.
Estimation of oxidative stress in cell cultures. An aliquot of cells was taken from the cultivation medium. The medium was replaced with PBS buffer to obtain a cell suspension containing 10 6 cells/mL. A solution of 2',7'-dichlorodihydrofluorescin diacetate (DCFH-DA, 1 L, 5 mM in DMSO) was added to the cell suspension (1 mL) and incubated in the dark for 30 min at room temperature. Afterwards, the fluorescence of the samples ( ex = 488 nm, em = 530 nm) was determined by using the flow cytometer.
Assay for Determination of Cell Permeability of the Prodrugs
Cells grown in RPMI 1640 medium supplemented with 10% FBS (20% for BL-2), 1%
glutamine, and 1% penicillin/streptomycin were centrifuged, and the medium was replaced with RPMI 1640 medium (5% FCS, 1% L-glutamine, 1% penicillin/streptomycin) to obtain suspensions containing 10 
Effect of the compounds on the viability of cell lines
The cells were centrifuged, the medium was removed, and the cells were washed two times with PBS buffer and re-suspended in the RPMI 1640 medium containing 5% FBS, 1% L-glutamine, and 1% penicillin/streptomycin. This suspension was spread in the wells of a 96-well microtiter plate (50 000 cells per well per 100 L). Stock solutions of prodrugs of different concentrations Experiments with primary CLL cells were conducted as described elsewhere. 9 The viability of CLL cells was determined by ATPlite™ Luminescence Assay System (PerkinElmer, Waltham, USA). The cells were incubated in medium containing human serum (HS). TP53 mutation status in CLL cells was determined as described elsewhere.
26,27
Preparation of rat Precision-Cut Liver Slices (PCLS) and toxicity studies ex vivo. Male Wistar rats (Charles River, Sulzfeld, Germany) of 250-450 g were housed under a 12 h dark/light cycle at constant humidity and temperature. Animals were permitted free access to tap water and standard lab chow. All experiments were approved by the committee for care and use of laboratory animals of the University of Groningen and were performed according to strict governmental and international guidelines. For determination of the antitumor activity the prodrug was introduced intraperitoneally everyday (for 6 days) starting from the second day after injection of L1210 cells. The latter cells (10 6 cells/animal) were introduced intraperitoneally. The animals were divided in two groups, each containing 15 animals. The first group served as control and received 0.5 mL of the physiological solution (PBS). Animals in the other group were treated during 6 days with prodrug 4 at a dose of 26 µg/kg per day. 24 h after the last injection of the prodrug solution ascites fluid was taken out of animals. In this experimental model ascites fluid contained over 93 % of L1210 cells with respect to the total cell number. 25 The integrity of mitochondria (JC-1 assay, Life Technologies) and the concentration of ROS (CM-H2DCF DA assay, Life Technologies) were determined by using flow cytometry (Beckman Coulter, USA, excitation laser 488 nm, emission channels: FL1 -525 nm, FL2 -575 nm). 
Measurements of intracellular ROS in L1210 cells
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